Oseltamivir Dosing in Critically III Patients With Severe Influenza
Identifieur interne : 001051 ( Main/Exploration ); précédent : 001050; suivant : 001052Oseltamivir Dosing in Critically III Patients With Severe Influenza
Auteurs : Alexander H. Flannery [États-Unis] ; Melissa L. Thompson Bastin [États-Unis]Source :
- The Annals of pharmacotherapy [ 1060-0280 ] ; 2014.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
Abstract
Objective: To evaluate the literature for published reports regarding the efficacy of standard versus higher dosing of oseltamivir in critically ill patients with severe influenza. Data Sources: An English-language literature search was conducted using MEDLINE (1966-February 2014) using the terms oseltamivir and influenza limited to humans and adults older than 19 years. Additional articles were identified through a manual search of the references obtained from the MEDLINE search. Study Selection and Data Extraction: Articles were manually screened for inclusion related to pharmacokinetic or clinical studies comparing varying doses of oseltamivir, particularly in the critically ill patient population. Studies investigating the pharmacokinetics of oseltamivir in continuous renal replacement therapy (CRRT) and extracorporeal membrane oxygenation (ECMO) were also included. Data Synthesis: During the 2009 HINI influenza pandemic, the World Health Organization suggested 150 mg twice daily as a consideration in critically ill patients with severe influenza. The basis for the recommendation can be traced back to animal studies investigating the H5NI virus. Three different studies in humans investigating higher doses in severe influenza have found no differences in clinical outcomes between standard and higher dosing. Pharmacokinetic studies suggest adequate absorption in critically ill patients. Although no dosage adjustment appears to be needed for ECMO patients, reduction may berequired for CRRT.. Conclusions:. Although additional data are needed for a definitive conclusion, the small body of literature available in humans does not support routine use of high-dose oseltamivir in critically ill patients.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000045
- to stream PascalFrancis, to step Curation: 001D74
- to stream PascalFrancis, to step Checkpoint: 000059
- to stream Main, to step Merge: 001060
- to stream Main, to step Curation: 001051
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Oseltamivir Dosing in Critically III Patients With Severe Influenza</title><author><name sortKey="Flannery, Alexander H" sort="Flannery, Alexander H" uniqKey="Flannery A" first="Alexander H." last="Flannery">Alexander H. Flannery</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>University of Kentucky HealthCare</s1><s2>Lexington, KY</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Kentucky</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>University of Kentucky College of Pharmacy</s1><s2>Lexington, KY</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Kentucky</region></placeName></affiliation></author><author><name sortKey="Thompson Bastin, Melissa L" sort="Thompson Bastin, Melissa L" uniqKey="Thompson Bastin M" first="Melissa L." last="Thompson Bastin">Melissa L. Thompson Bastin</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>University of Kentucky HealthCare</s1><s2>Lexington, KY</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Kentucky</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>University of Kentucky College of Pharmacy</s1><s2>Lexington, KY</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Kentucky</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">14-0220950</idno><date when="2014">2014</date><idno type="stanalyst">PASCAL 14-0220950 INIST</idno><idno type="RBID">Pascal:14-0220950</idno><idno type="wicri:Area/PascalFrancis/Corpus">000045</idno><idno type="wicri:Area/PascalFrancis/Curation">001D74</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000059</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000059</idno><idno type="wicri:doubleKey">1060-0280:2014:Flannery A:oseltamivir:dosing:in</idno><idno type="wicri:Area/Main/Merge">001060</idno><idno type="wicri:Area/Main/Curation">001051</idno><idno type="wicri:Area/Main/Exploration">001051</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Oseltamivir Dosing in Critically III Patients With Severe Influenza</title><author><name sortKey="Flannery, Alexander H" sort="Flannery, Alexander H" uniqKey="Flannery A" first="Alexander H." last="Flannery">Alexander H. Flannery</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>University of Kentucky HealthCare</s1><s2>Lexington, KY</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Kentucky</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>University of Kentucky College of Pharmacy</s1><s2>Lexington, KY</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Kentucky</region></placeName></affiliation></author><author><name sortKey="Thompson Bastin, Melissa L" sort="Thompson Bastin, Melissa L" uniqKey="Thompson Bastin M" first="Melissa L." last="Thompson Bastin">Melissa L. Thompson Bastin</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>University of Kentucky HealthCare</s1><s2>Lexington, KY</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Kentucky</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>University of Kentucky College of Pharmacy</s1><s2>Lexington, KY</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Kentucky</region></placeName></affiliation></author></analytic><series><title level="j" type="main">The Annals of pharmacotherapy</title><title level="j" type="abbreviated">Ann. pharmacother.</title><idno type="ISSN">1060-0280</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">The Annals of pharmacotherapy</title><title level="j" type="abbreviated">Ann. pharmacother.</title><idno type="ISSN">1060-0280</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral</term><term>Human</term><term>Influenza</term><term>Intensive care</term><term>Oseltamivir</term><term>Posology</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Oséltamivir</term><term>Posologie</term><term>Homme</term><term>Grippe</term><term>Soin intensif</term><term>Antiviral</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objective: To evaluate the literature for published reports regarding the efficacy of standard versus higher dosing of oseltamivir in critically ill patients with severe influenza. Data Sources: An English-language literature search was conducted using MEDLINE (1966-February 2014) using the terms oseltamivir and influenza limited to humans and adults older than 19 years. Additional articles were identified through a manual search of the references obtained from the MEDLINE search. Study Selection and Data Extraction: Articles were manually screened for inclusion related to pharmacokinetic or clinical studies comparing varying doses of oseltamivir, particularly in the critically ill patient population. Studies investigating the pharmacokinetics of oseltamivir in continuous renal replacement therapy (CRRT) and extracorporeal membrane oxygenation (ECMO) were also included. Data Synthesis: During the 2009 HINI influenza pandemic, the World Health Organization suggested 150 mg twice daily as a consideration in critically ill patients with severe influenza. The basis for the recommendation can be traced back to animal studies investigating the H5NI virus. Three different studies in humans investigating higher doses in severe influenza have found no differences in clinical outcomes between standard and higher dosing. Pharmacokinetic studies suggest adequate absorption in critically ill patients. Although no dosage adjustment appears to be needed for ECMO patients, reduction may berequired for CRRT.. Conclusions:. Although additional data are needed for a definitive conclusion, the small body of literature available in humans does not support routine use of high-dose oseltamivir in critically ill patients.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Kentucky</li></region></list><tree><country name="États-Unis"><region name="Kentucky"><name sortKey="Flannery, Alexander H" sort="Flannery, Alexander H" uniqKey="Flannery A" first="Alexander H." last="Flannery">Alexander H. Flannery</name></region><name sortKey="Flannery, Alexander H" sort="Flannery, Alexander H" uniqKey="Flannery A" first="Alexander H." last="Flannery">Alexander H. Flannery</name><name sortKey="Thompson Bastin, Melissa L" sort="Thompson Bastin, Melissa L" uniqKey="Thompson Bastin M" first="Melissa L." last="Thompson Bastin">Melissa L. Thompson Bastin</name><name sortKey="Thompson Bastin, Melissa L" sort="Thompson Bastin, Melissa L" uniqKey="Thompson Bastin M" first="Melissa L." last="Thompson Bastin">Melissa L. Thompson Bastin</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001051 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001051 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:14-0220950
|texte= Oseltamivir Dosing in Critically III Patients With Severe Influenza
}}
| This area was generated with Dilib version V0.6.34. |  |